Drug-Eluting Stent Benefits Do Not Outweigh Price Tag – Lancet Study
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stent use could be restricted to certain high-risk patient subgroups until the price of the stents is reduced, according to a cost-effectiveness study presented Sept. 6 at the European Society of Cardiology meeting in Stockholm
You may also be interested in...
Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC
Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus
Drug-Eluting Stents Will Pay Their Own Way According To SIRIUS Cost Study
The additional costs associated with implanting Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent instead of a bare metal stent are almost entirely recouped within the first year post-implant, according to a cost-effectiveness analysis of the SIRIUS trial
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.